Updated May 1, 2022
Michelle Edwards with Uncover DC writes, “The U.S. Food and Drug Administration (FDA) announced on Monday the approval of Veklury (remdesivir) to treat infants 28 days and older weighing at least 7 pounds with positive results of SARS-CoV-2 viral testing and are either hospitalized or have mild to moderate COVID-19 and are at high risk for progression to severe COVID-19.
Prior to this approval for infants and children, the drug was only approved to treat “certain adults” and pediatric patients 12 years of age and older who weigh at least 88 pounds. In a news release, the FDA explained that part of the rationale behind the approval of Veklury for infants and young children is that there is no alternative “safe and effective treatment,” including the COVID-19 experimental “vaccine,” which is currently not approved for children under five.
Access the complete article here
Dr. Meryl Nass for Children’s Health Defense on April 28, 2022 was interviewed and states, “You’ve got a dangerous drug that’s now going to be tested in babies, it’s fully approved but everyone who gets it is going to be a guinea pig because no proper studies are being done. The FDA Approved Remdesivir Based on a Trial in Which 3 out of 53 Children Died.
The trial was conducted by Gilead, the developer of Remdesivir and there was no control group. Without a control group, it’s unclear how either Gilead or the FDA determined that the drug benefited children because there’s nothing to compare it to. The FDA collaboration to approve a dangerous drug like Remdesivir for infants as young as 28 days old reminds her of the Tamiflu effort in which Gilead ‘massaged’ data in order to get FDA approval. Over 70% had an adverse reaction, 21% had a serious adverse event, and three of the children died.
The mortality rate of children with no treatment against COVID is 0.005% (1 in 20,000 die).
The mortality rate of children with Remdesivir treatment is 5.66% (1 in 17.7 die) based on this trial.
Access the full 8 minute video with Dr. Nass here
April 5, 2022
Remdesivir Study in Europe Shows No Difference in Recovery Rates in Hospitalized Patients
According to Sky News, Remdesivir once hailed as “biggest step forward in the treatment of coronavirus since the crisis began has failed to show any benefit in randomised controlled trials. The drug was developed to treat Ebola. The US bought up almost the entire global supply from US pharmaceutical giant Gilead Sciences. It was approved for use there.
In five European countries, researchers studied 843 COVID-19 patients who were hospitalised between March 2020 and January 2021 and who needed oxygen or machines to help with breathing. Two weeks after patients had received either the antiviral Remdesivir plus standard of care, or standard of care alone, for up to 10 days, there was no difference between the groups in signs of improvement.”
Access the Complete Remdesivir Study here
September 20, 2020
Shocking Remdesivir facts related to Anthony Fauci, past studies
Dr. Ardis covers some of the more shocking Remdesivir facts related to Anthony Fauci, past studies, 2020 mortality and cause of death, organ failure and current hospital treatment protocols that are killing patients in ICUs across this nation.
He addresses the FDA’s Vaccine Safety Surveillance working list of adverse events that are not being provided to persons receiving the vaccines.
Access Dr. Ardis’ ten minute address at the Reawaken America tour here
